Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the development of an inflammatory risk score to identify patients with multiple myeloma at risk of severe inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) treatment. The study identified that a cytokine signature associated with macrophage activity was associated with more severe adverse events. This score may be used to guide risk adapted management of CAR-T therapy and its related side effects.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.